Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IT7-H52W4 | Human | Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free |  |
|
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo | Tysabri, Antegran, Antegren | Japan | Multiple Sclerosis | Biogen Inc | 2004-11-23 | Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Myeloma; Stroke; Crohn Disease | Details |
| Vedolizumab | LDP-02; LPD-02; MLN-02; MLN-002; MLN-0002 | Approved | Millennium Pharmaceuticals Inc | 安吉优, Entyvio | Mainland China | Colitis, Ulcerative; Crohn Disease | Takeda Pharma A/S | 2014-05-20 | Hematopoietic stem cell transplantation (HSCT); Inflammatory Bowel Diseases; Cholangitis, Sclerosing; Colitis, Ulcerative; Crohn Disease; Melanoma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Natalizumab biosimilar (Polpharma Biologics) | PB-006 | Phase 3 Clinical | Polpharma Biologics | Multiple Sclerosis | Details |
| PN-10943A | PN-943; PN-10943; PN-10943-A | Phase 2 Clinical | Protagonist Therapeutics | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
| Ontamalimab | SHP-647; PF-547659; PF-00547659 | Phase 3 Clinical | Pfizer Inc | Ileitis; Colitis, Ulcerative; Crohn Disease | Details |
| Etrolizumab | R-7413; RG-7413; PRO-145223; rhuMAb-Beta7 | Phase 3 Clinical | Genentech Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease | Details |
| MORF-057 | MORF-057 | Phase 1 Clinical | Morphic Therapeutic | Inflammatory Bowel Diseases | Details |
This web search service is supported by Google Inc.
A-Z